InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, has announced that it will release its fiscal year 2021 financial report at the end of the week. INM’s full financial statements and related MD&A for the period ending June 30, 2021, will be released on Friday, Sept. 24, 2021. In connection with the release of its financial report, the company will also be hosting a conference call/webcast to discuss the report. The call will begin at 11 a.m. ET. Interested individuals from the United States and Canada can call toll free at 855-605-1745; those who are interested and need to dial in internationally can call 914-987-7959. Callers will need to use conference ID #9373618. A recording of the webcast will be available for 90 days following the event. In addition, InMed announced that it has signed a definitive agreement to acquire BayMedica, a private company based in the United States that specializes in the manufacture and commercialization of rare cannabinoids. The agreement outlines the acquisition terms, which involve an all-stock transaction. According to the announcement, InMed will issue 1.78 million shares to BayMedica’s equity and convertible debt holders, an estimated $4 million value. The strategic move, which will likely close in the coming weeks, will provide InMed with established expertise in yeast and bacteria biosynthesis as well as chemical synthesis of cannabinoids. The company also noted that the move represents cumulative revenues for InMed of more than $2.5 million since December 2019; those revenues are from the sale of cannabichromene (“CBC”).
To view the full webinar, visit https://ibn.fm/8h0xJ
To view the full press releases, visit https://ibn.fm/XKM71 and https://ibn.fm/gi8O6
About InMed Pharmaceuticals Inc.
InMed Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol (“CBN”); the company is developing IntegraSyn(TM) to produce pharmaceutical-grade cannabinoids. INM is dedicated to delivering new therapeutic alternatives to patients who may benefit from cannabinoid-based medicines. For more information, please visit www.InMedPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.